You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.
The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.
A single-cell RNA sequencing analysis suggests progression to multiple myeloma involves shifts in immune cell representation and activity in the microenvironment.
The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.
The firms plan to discover and develop fully human neutralizing antibodies that target the SARS-CoV-2 virus, combining Adaptive's and Amgen's respective expertise.
The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.
Illumina, LabCorp, and Providence healthcare will join the effort to collect COVID-19 patient samples in the US for immune cell receptor sequencing.
The immune sequencing firm has engaged the FDA in discussions over how to get regulatory approval for one test for several seemingly different diseases.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.